Ocella

Ocella is a biotechnology company focused on developing next-generation "off-the-shelf" cell therapies using induced pluripotent stem cell (iPSC) technology. The company leverages a proprietary, non-viral, protein-based reprogramming platform to generate high-quality, clinical-grade iPSCs and their derivatives. Founded by leading stem cell researchers from Johns Hopkins University, Ocella aims to overcome the limitations of current autologous cell therapies by providing scalable and standardized cellular products. The company's technology is designed to produce various therapeutic cell types for applications in oncology, hematology, and regenerative medicine.